A game-changing therapy: early insulin for the control of type 2 diabetes
Location: Beijing, China
Study Overview:
Chinese scientists led by Professor Weng Jianping of Anhui Medical University, along with researchers from the University of Science and Technology of China, Southern Medical University and Peking University, conducted a 24-year observational study on the treatment of 5,424 newly diagnosed patients. Type 2 diabetes (T2D) nationwide.
Low risk:
Newly diagnosed T2D patients who underwent early insulin therapy experienced significant benefits compared to those who did not receive treatment. Specifically, they had a 31 percent lower risk of stroke and a 28 percent lower risk of hospitalization for heart failure.
Better Biomarkers:
The study also highlighted improvements in biomarkers related to low-grade inflammation and endothelial function, which are important indicators of cardiovascular risk in newly diagnosed T2D patients.
First-line treatment option:
The results provide compelling evidence for considering early insulin therapy as a first-line treatment option for patients newly diagnosed with type 2 diabetes.
Publication:
The study results, published in early June in the International Journal of Signal Transduction and Targeted Therapy, highlight the potential of early insulin therapy to revolutionize the management of type 2 diabetes.
